{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.9","upperLimit":"44.6","value":"25.8"},{"groupId":"OG001","lowerLimit":"15.3","upperLimit":"50.8","value":"31.0"}]}],"title":"Erythroid response (HI-E)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.2","upperLimit":"54.6","value":"35.5"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"43.5","value":"24.1"}]}],"title":"Platelet response (HI-P)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"37.5","value":"19.4"},{"groupId":"OG001","lowerLimit":"3.9","upperLimit":"31.7","value":"13.8"}]}],"title":"Neutrophil response (HI-N)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"Hematologic response consists of Erythroid response (HI-E), Platelet response (HI-P) and Neutrophil response (HI-N).\n\nHI-E: Hgb increase by ≥ 1.5 g/dL over pretreatment \\& relevant reduction of units of RBC transfusions by an absolute number of at least 4 units of PRBCs/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for a Hgb of ≤ 9.0 g/dL pretreatment will count in the RBC transfusion response evaluation.\n\nHI-P: Absolute increase of ≥ 30 x 109/L over pretreatment or patients starting with ≥ 20 x 109/L platelets OR increase from \\<20 x 109/L at pretreatment to \\> 20 x 109/L and by at least 100%.\n\nHI-N: At least 100% increase and an absolute increase \\> 0.5 x 109/L over pretreatment value.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.\n\nIn both phases, dose of 5-Azacytidine was 75 mg/m\\^2, subcutaneously Daily for Day 1 to Day 7.","id":"OG000","title":"Panobinostat + 5-Azacytidine"},{"description":"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.\n\nDose of 5-Azacytidine : 75 mg/m\\^2 subcutaneously daily from Day 1 to Day 7.","id":"OG001","title":"5-Azacytidine"}],"paramType":"NUMBER","populationDescription":"Full analysis set: Consisted of all patients who were randomized to one of the two treatment arms","reportingStatus":"POSTED","timeFrame":"48 months","title":"Hematologic Improvement (HI) for Myeloid Dysplastic Syndromes(MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Per Investigator (Phase Llb)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}